HOME >> BIOLOGY >> NEWS
New gene therapy shows promise for hemophiliacs

MINNEAPOLIS / ST. PAUL -- University of Minnesota researchers have demonstrated that it may be possible to treat hemophilia A through the use of human blood outgrowth endothelial cells, or BOECs, as a vehicle for gene therapy. Lead researcher Robert Hebbel, M.D., the George Clark Professor and vice chair for research, department of medicine, reports that the use of BOECs has "resulted in sustained and therapeutic levels of factor 8 (FVIII) in mice and may comprise an effective therapeutic strategy for use in gene therapy for humans with hemophilia A." The results of this gene therapy, published in the January 15 issue of Blood, may pave the way for testing the therapy in humans.

Hemophilia A is an inherited blood disorder that affects one in 5,000 males and results in spontaneous bleeding due to the lack of coagulation factor 8 (FVIII) in the blood. Because hemophilia is such a severe disease, and because it is caused by absence of a replaceable blood protein, there has been a high level of interest in developing a gene therapy approach for its treatment. While there are currently some ongoing Phase I clinical studies of gene therapy for humans for hemophilia B (a related disorder that affects a different coagulation factor), development of gene therapy for hemophilia A has lagged behind. Current clinical therapy generally calls for the replacement of factor VIII after the patient has had some trouble.

The ex vivo process devised by Hebbel utilizes BOECs as carriers for gene therapy. The process begins with a blood sample taken from the patient as a source for autologous BOECs. (This use of autologous cells eliminates the concern for immunological compatibility or disease-tainted blood sources). The BOECs are separated from the blood and cultured in the lab and then transfected with a nonviral plasmid vector carrying the gene for human coagulation factor VIII. After allowing them to further expand, those stably transfected BOECs are then given
'"/>

Contact: Deane Morrison
morri029@umn.edu
612-624-2346
University of Minnesota
18-Jan-2002


Page: 1 2

Related biology news :

1. Targeted therapy knocks out pediatric brain cancer in mice
2. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
3. Columbia research to examine gene influence on severity of peridontal disease, therapy response
4. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
5. The search for a kinder, gentler chemotherapy
6. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
7. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
8. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
9. Jefferson Lab detector technology aids development of cystic fibrosis therapy
10. Stroking up cellular therapy
11. Smart gene therapy protects against damage from heart attack

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New gene therapy shows promise for hemophiliacs

(Date:3/20/2015)... Conn. , March 20, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... smart wallet is one of the products featured in ... March 20th at 11:00 PM EST on the DIY ... to Las Vegas , site of ...
(Date:3/17/2015)... 2015 Emotient, the leader in facial ... general availability of Emotient Analytics , the ... of facial expressions. The system analyzes videos of ... and services. It delivers audience response metrics - ... as derived from facial evidence of emotional states. ...
(Date:3/12/2015)... BERLIN , March 12, 2015 ... IAM, a standardized identity and access management (IAM) ... reliable implementation schedule. With Beta System,s new IAM ... and best practices gleaned from multiple IAM implementations ... includes the software as well as any necessary ...
Breaking Biology News(10 mins):NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
(Date:4/2/2015)... 02, 2015 InGaAs PIN photo diodes ... sensitivity and high-speed response. Marktech introduces the newest series ... can with active areas of 0.1mm, 0.3mm and 0.8mm. ... and high speed fiber modules. , Standard spectral range ... These parts offer considerable speed improvements over the current ...
(Date:4/1/2015)... , April 1, 2015  Adaptive Biotechnologies ... The Lancet Oncology showing that ... company,s next-generation sequencing-based minimal residual disease (MRD) detection ... MRD test) accurately identifies patients with diffuse large ... relapse after initial treatment, usually several months before ...
(Date:4/1/2015)... -- Emerson Ecologics is excited to announce its first ... . The conference will provide integrative healthcare practitioners with ... fulfilling practice. Scheduled for November 13-15, ... the conference will be a one-of-a-kind, "get it done" ... and leave with an action plan in hand. Highlights ...
(Date:4/1/2015)... , April 1, 2015  ValGenesis Inc., the market ... today that it has completed its Service Organization Controls ... Engagements (AICPA, Professional Standards) for the period of January ... 2014.  ... The SOC 2 examination ...
Breaking Biology Technology:Marktech Optoelectronics Announces High Speed InGaAs PIN Diode 1.7µm 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 2Emerson Ecologics Announces First Annual Conference for Integrative Healthcare Practitioners 3ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 2ValGenesis Inc. Successfully Completes Service Organization Controls 2 (SOC 2) Report under AT Section 101 3
Cached News: